Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Total Valuation
Trevi Therapeutics has a market cap or net worth of $1.53B. The enterprise value is $1.51B.
Market Cap$1.53B
Enterprise Value$1.51B
Share Statistics
Trevi Therapeutics has 128,397,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,397,280
Owned by Insiders1.51%
Owned by Institutions57.40%
Financial Efficiency
Trevi Therapeutics’s return on equity (ROE) is -0.23 and return on invested capital (ROIC) is -26.77%.
Return on Equity (ROE)-0.23
Return on Assets (ROA)-0.22
Return on Invested Capital (ROIC)-26.77%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee0.00
Profits Per Employee-1.38M
Employee Count31
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Trevi Therapeutics is ―. Trevi Therapeutics’s PEG ratio is 1.11.
PE Ratio―
PS Ratio0.00
PB Ratio9.91
Price to Fair Value9.91
Price to FCF-43.15
Price to Operating Cash Flow-41.28
PEG Ratio1.11
Income Statement
In the last 12 months, Trevi Therapeutics had revenue of 0.00 and earned -42.76M in profits. Earnings per share was -0.29.
Revenue0.00
Gross Profit-132.00K
Operating Income-49.33M
Pretax Income-42.82M
Net Income-42.76M
EBITDA-49.33M
Earnings Per Share (EPS)-0.29
Cash Flow
In the last 12 months, operating cash flow was -42.09M and capital expenditures 13.46M, giving a free cash flow of -28.62M billion.
Operating Cash Flow-42.09M
Free Cash Flow-28.62M
Free Cash Flow per Share-0.22
Dividends & Yields
Trevi Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.46
52-Week Price Change97.36%
50-Day Moving Average11.24
200-Day Moving Average9.89
Relative Strength Index (RSI)55.76
Average Volume (3m)2.56M
Important Dates
Trevi Therapeutics upcoming earnings date is May 7, 2026, After Close (Confirmed).
Last Earnings DateMar 17, 2026
Next Earnings DateMay 7, 2026
Ex-Dividend Date―
Financial Position
Trevi Therapeutics as a current ratio of 19.66, with Debt / Equity ratio of 0.41%
Current Ratio19.66
Quick Ratio19.66
Debt to Market Cap<0.01
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Trevi Therapeutics has paid -64.00K in taxes.
Income Tax-64.00K
Effective Tax Rate<0.01
Enterprise Valuation
Trevi Therapeutics EV to EBITDA ratio is -36.46, with an EV/FCF ratio of -42.72.
EV to Sales0.00
EV to EBITDA-36.46
EV to Free Cash Flow-42.72
EV to Operating Cash Flow-42.73
Balance Sheet
Trevi Therapeutics has $188.26M in cash and marketable securities with $753.00K in debt, giving a net cash position of $187.51M billion.
Cash & Marketable Securities$188.26M
Total Debt$753.00K
Net Cash$187.51M
Net Cash Per Share$1.46
Tangible Book Value Per Share$1.26
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Trevi Therapeutics is $22.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$22.00
Price Target Upside63.33% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast15.84%